What's better than a stock that has delivered huge gains? That's easy: A stock that has delivered huge gains and still has a lot of room to run. We asked three Motley Fool contributors to look among recently high-flying stocks for those that they believe could soar by significantly more. Here's why they ...
motleyfoolusx:llyusx:vrtxusx:nvo
There are many stocks that you can invest in for the long haul and effectively forget about. These are businesses with robust financials, strong growth prospects, and a lot of stability for investors. They are what you would consider to be blue chip stocks. Three of the best blue chip stocks to buy, ...
motleyfoolusx:aaplusx:wmtusx:lly
Eli Lilly (NYSE: LLY) can't stop grabbing headlines. The pharmaceutical company has made quite a bit of noise over the past few years thanks to notable clinical and regulatory progress. Investors have rewarded the drugmaker accordingly -- Eli Lilly's shares have vastly outperformed the broader market ...
motleyfoolusx:lly
Eli Lilly's (NYSE: LLY) broad portfolio of drugs has helped the company's earnings climb over the years -- and in recent times, two products in particular have supercharged growth. The big pharma company sells Mounjaro and Zepbound, both prescribed for weight loss, and demand has been surpassing supply. ...
motleyfoolusx:lly
I’m sure you would have come across an advice that goes something along the lines of, ‘you can get an exposure to listed companies around the world when you invest in the iShares MSCI World ETF (NYSE ARCA: URTH).’ The first thing on your mind the first time you hear about this suggestion will probably ...
ljunyuansgx:c09sgx:a17usgx:o39sgx:z74sgx:c31sgx:d05sgx:s68sgx:bn4sgx:u11sgx:s63sgx:c6lsgx:g13sgx:f34sgx:m44uusx:googusx:googlsgx:c70usx:aaplusx:amznsgx:v03usx:msftusx:jpmusx:nvdausx:llyusx:avgousx:forusx:meta
Eli Lilly (NYSE: LLY) sells a broad portfolio of products, but two in particular have helped revenue growth explode in recent times. I'm talking about Lilly drugs that doctors prescribe for weight loss: Mounjaro and Zepbound. They're both based on the same molecule, but regulators approved the product ...
motleyfoolusx:llyusx:amgn
Drugmakers outside the biosimilar or generic-medicine market must constantly innovate to be successful over long periods. Some are better at it than others. Eli Lilly (NYSE: LLY) and Regeneron Pharmaceuticals (NASDAQ: REGN) have historically been in the more successful group. That's why they are among ...
motleyfoolusx:regnusx:lly
It's a truism in the stock market that winners tend to keep winning. For pharmaceutical companies, making good on that axiom requires a lot of hard work to develop new medicines, and to find ways of adding to established markets that are addressable by their existing drug portfolios. But the best competitors ...
motleyfoolusx:lly
Excellent, magnificent, fantastic! All of these superlatives (and more) describe Eli Lilly's (NYSE: LLY) performance in recent years as it has delivered market-crushing returns and strong regulatory progress. Though the stock might peak eventually, we aren't there yet, as the pharmaceutical giant proved ...
motleyfoolusx:lly
The healthcare industry is a fantastic place to find passive income. Healthcare is recession-proof, and there's always a need for better technology and new treatments. The industry's top dogs have been in the game for decades and can generate wealth for patient shareholders who come along for the ride. ...
motleyfoolusx:abbvusx:llyusx:nvo
A company's track record for paying dividends is a good indicator of how versatile and adaptable the business is in dealing with changing economic conditions. That doesn't mean that the dividend will always be safe and that payouts will always continue, but it's an important factor that dividend investors ...
motleyfoolusx:kousx:llyusx:td
The pharmaceutical industry is currently experiencing something of a renaissance thanks to the rise of blockbuster medications called glucagon-like peptide-1 (GLP-1) agonists. Perhaps the most well-known GLP-1 drugs are diabetes medication Ozempic and obesity care treatment Wegovy. Danish pharmaceutical ...
motleyfoolusx:lly
Eli Lilly (NYSE: LLY) stock has been a top performer thanks to runaway sales of its diabetes-turned-weight-management treatment. Despite nearly doubling over the past 12 months, Eli Lilly stock still has heaps of upside according to investment bank analysts who follow the century-old pharmaceutical giant. ...
motleyfoolusx:lly
By almost any measure, Eli Lilly (NYSE: LLY) stock has been a standout so far in 2024. Using a basic yardstick, the pharmaceutical sector giant's share price has climbed by over 33%, against the S&P 500 index's 5%. A mix of well-established commercialized drugs, a robust pipeline, and the company's recent ...
motleyfoolusx:lly
Image source: The Motley Fool. Eli Lilly (NYSE: LLY) Q1 2024 Earnings Call Apr 30, 2024, 10:00 a.m. ET Operator Continue reading
motleyfoolusx:lly
Shares of Eli Lilly and Company (NYSE: LLY) were jumping 6% higher as of 11:03 a.m. ET on Tuesday. The solid gain came after the big drugmaker announced its first-quarter 2024 results. Lilly reported Q1 revenue of $8.77 billion, up 26% year over year. This result came in a little below the average analyst's ...
motleyfoolusx:lly
Eli Lilly and Company (NYSE: LLY) reported first quarter 2024 earnings results today. Worldwide revenue was $8.77 billion, up 26% from the year-ago quarter, driven by increases of 16% in volume and 10% due to higher realized prices. Reported net income increased 67% to $2.24 billion, or $2.48 per share, ...
alphastreetusx:lly
Eli Lilly (NYSE: LLY), a juggernaut on the stock exchange with a $700 billion-plus market capitalization, has a lot going for it these days that should encourage investors. After all, its products are at the forefront of treating diabetes and weight loss. But one thing investors shouldn't expect are ...
motleyfoolusx:lly
The pharmaceutical business is a tricky one. Developing novel therapies costs hundreds of thousands of dollars, sometimes more. Many never make it to the market despite substantial sums invested by drugmakers. Many of those that do earn approval end up falling short of sales expectations. However, occasionally, ...
motleyfoolusx:lly
Nvidia has been an amazing stock to own over the past few years, generating incredible returns for investors. But the risk is that expectations may be too high for the stock, especially with respect to artificial intelligence (AI). And that means the stock could be vulnerable to a sell-off if reality ...
motleyfoolusx:llyusx:nvousx:unh
One of the hottest areas in the pharmaceutical space right now is weight loss. Glucagon-like peptide-1 (GLP-1) medications such as Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound have become staples for treating diabetes and obesity. Eli Lilly (NYSE: LLY) is the developer of Mounjaro and Zepbound, ...
motleyfoolusx:lly
No risk, no reward. That's a fundamental part of investing. However, some stocks are less risky than others and still offer strong growth prospects. Three Motley Fool contributors think they've found relatively safe growth stocks you can buy and hold. Here's why they picked Eli Lilly (NYSE: LLY), Novo ...
motleyfoolusx:llyusx:vrtxusx:nvo
For both the biotech and pharmaceutical industries, what happens in the laboratory is critical to success (or failure, on the flip side). Some good news from a clinical trial conducted by Eli Lilly (NYSE: LLY) boosted the share price of the pharmaceutical giant (by 0.5%) on Wednesday, leaving several ...
motleyfoolusx:llyusx:ahcousx:rmd
Does a 100% return in less than seven years sound pretty good? Most investors would probably say so. But which stocks are good candidates to achieve such a gain? Three Motley Fool contributors think they've found magnificent stocks that could double or more by 2030. Here's why they picked CRISPR Therapeutics ...
motleyfoolusx:llyusx:vktxusx:crsp
Shares of Swiss pharmaceuticals giant Roche Holdings (OTC: RHHBY) stock popped 2.5% in early trading Thursday before giving back about half of its gains. Roche announced this morning that the U.S. Food and Drug Administration has awarded the "Breakthrough Device Designation" to its new Elecsys pTau217 ...
motleyfoolusx:lly
